Express delivery and free returns within 21 days

Saturday, July 2, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

BD Completes Clinical Trial for BD Libertas™ Wearable Injector Completed

- Advertisement -

Becton, Dickinson and Company) today announced the completion of a 50-subject human clinical trial with the BD Libertas™ Wearable Injector.

The award-winning injector* is a subcutaneous drug delivery system, currently, in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.

The BD independently sponsored and conducted study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity, and patient acceptance. The results are expected to be announced in early 2020.

The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas™ Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.

Commenting on the study, Peter Nolan, Worldwide President, BD Pharmaceutical Systems, said, “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img

Other News of Interest

Executives on the Move

By using this website you agree to accept Medical Device News Magazine Privacy Policy